Skip to content
Alligator Bioscience

Alligator Bioscience

sv
  • About Alligator
    • Board of directors
    • Management
    • Collaborations and partnerships
    • Career
  • Research & development
    • Immunotherapy of cancer
    • Pipeline
      • ADC-1013 (mitazalimab)
      • ATOR-1015
      • ATOR-1017
      • ALG.APV-527
      • ATOR-1144
      • Research projects
    • Scientific publications
    • Technology platform
      • ALLIGATOR-GOLD®
      • FIND®
    • Scientific advisors and collaborators
  • Corporate governance
    • General meeting
    • Board of Directors and Management
    • Nomination committee
    • Audit Committee
    • Remuneration Committee
    • Remuneration
    • Auditors
    • Articles of association
    • Internal control
  • Investors
    • Share and shareholders
    • Analysts
    • IPO
    • Financial reports
      • Annual reports
      • Interim reports
    • Calendar
    • Presentations
    • Subscribe
  • News
    • Press releases
    • Frontier – A magazine about Alligator
    • Subscribe
  • Contact
  • SV

  • Alligator Bioscience - Innovating Tumor-Directed Immunotherapy

  • Cancer cure is our passion - research is our foundation

  • Tumor-directed immunotherapies for major unmet medical needs within cancer

  1. 1
  2. 2
  3. 3

Latest News

  • 17 Dec 2019 – Alligator Bioscience: First patient dosed with ATOR-1017 developed for metastasized cancer
  • 11 Dec 2019 – CFO Per-Olof Schrewelius leaves Alligator Bioscience
  • 29 Nov 2019 – Alligator Bioscience AB appoints Chief Operating Officer
  • 13 Nov 2019 – Nomination Committee appointed in respect of AGM 2020 in Alligator Bioscience AB
More news

Calendar

  • 28 Jan 2020 ‐ BIOMED event, Paris

The Alligator Movie

Watch the movie about Alligator Bioscience on youtube.

About

Alligator develops antibody-based pharmaceuticals for cancer treatment. The company specializes in the development of tumor-directed immunotherapies, in particular agonistic mono- and bispecific antibodies. The company is active in the early stages of drug development, from idea to clinical phase II studies.

Links

  • About Alligator
  • Research and development
  • Corporate governance
  • Investors
  • News
  • Contact

Contact

Alligator Bioscience AB
Medicon Village
Scheelevägen 2
SE-223 81 Lund
Sweden

Phone: + 46 (0)46 540 82 00

info@alligatorbioscience.com
ir@alligatorbioscience.com

Subscribe

Subscribe to get our pressreleases by email.

SUBSCRIBE

Alligator Bioscience

© Copyright 2018 - Alligator Bioscience AB

We use cookies for administering, monitoring and optimizing the website, and for analytical purposes, in accordance with what is stated in our cookie policy.I agreeI do not agree
Återkalla cookies